Equity Profile

ABBV

AbbVie Inc.

Health CareBiotechnology$443.2B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and performance, which investors closely monitor.

$3.61

Revenue

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

$16.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABBV Q2-2026 Earnings Preview

Context

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases. Operating in the health care sector, AbbVie is known for its innovative treatments and significant market presence, particularly in immunology and oncology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q1-2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the next day.

Management Promises & Guidance

Continued focus on expanding its immunology portfolio.
Commitment to maintaining strong revenue growth.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Analysts expect AbbVie to report solid earnings driven by its strong product lineup, with a consensus EPS of $3.61 and revenue of $16.8B.

Bull Case

If AbbVie exceeds expectations, it could signal strong demand for its products and boost investor confidence, potentially leading to a significant stock price increase.

Bear Case

Conversely, if AbbVie misses estimates or provides weak guidance, it may raise concerns about its growth prospects, leading to a decline in stock value.

Key Metrics to Watch

EPS

$3.61

Earnings per share is a key indicator of profitability and performance, which investors closely monitor.

Revenue

$16.8B

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will AbbVie achieve an EPS of $3.61 or higher?

This figure is critical as it reflects the company's profitability and could influence investor sentiment.

What guidance will AbbVie provide for future revenue growth?

Future revenue guidance will be closely watched as it indicates the company's growth trajectory and market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AbbVie's potential for growth in its immunology segment, which could outperform expectations this quarter.

Supporting Evidence

Recent product launches have shown strong market uptake, suggesting better-than-expected sales.

The options market indicates heightened volatility, which could reflect investor anticipation of positive news.

AbbVie has a history of beating EPS estimates, with an 88% success rate in the last eight quarters.

Key Risk

If AbbVie reports strong sales growth in its immunology products, it could significantly challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating AbbVie's ability to sustain growth amid competitive pressures and evolving market dynamics.

Bull Confirmed If

An EPS of $3.71 or higher would confirm strong demand for AbbVie's products.

Bear Confirmed If

An EPS below $3.54 would raise concerns about the company's growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±5.85%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±5.8% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

23.2%

Calls (444K)P/C Ratio: 0.73Puts (307K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests the stock could rise by an average of 1.78% on the following day, confirming strong demand.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may remain volatile as investors reassess growth prospects.

Miss

A miss could lead to a decline of around 0.15%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key products in the immunology segment.
2Any new developments in AbbVie's pipeline that could impact future growth.
3Management's insights on competitive pressures in the biotechnology space.
4Guidance on revenue expectations for the next quarter.
5Comments on market conditions and their impact on sales.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and performance, which investors closely monitor.

$3.61

Revenue

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

$16.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABBV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q1-2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the next day.

Management Promises & Guidance

Continued focus on expanding its immunology portfolio.
Commitment to maintaining strong revenue growth.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Analysts expect AbbVie to report solid earnings driven by its strong product lineup, with a consensus EPS of $3.61 and revenue of $16.8B.

Bull Case

If AbbVie exceeds expectations, it could signal strong demand for its products and boost investor confidence, potentially leading to a significant stock price increase.

Bear Case

Conversely, if AbbVie misses estimates or provides weak guidance, it may raise concerns about its growth prospects, leading to a decline in stock value.

Key Metrics to Watch

EPS

$3.61

Earnings per share is a key indicator of profitability and performance, which investors closely monitor.

Revenue

$16.8B

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will AbbVie achieve an EPS of $3.61 or higher?

This figure is critical as it reflects the company's profitability and could influence investor sentiment.

What guidance will AbbVie provide for future revenue growth?

Future revenue guidance will be closely watched as it indicates the company's growth trajectory and market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AbbVie's potential for growth in its immunology segment, which could outperform expectations this quarter.

Supporting Evidence

Recent product launches have shown strong market uptake, suggesting better-than-expected sales.

The options market indicates heightened volatility, which could reflect investor anticipation of positive news.

AbbVie has a history of beating EPS estimates, with an 88% success rate in the last eight quarters.

Key Risk

If AbbVie reports strong sales growth in its immunology products, it could significantly challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating AbbVie's ability to sustain growth amid competitive pressures and evolving market dynamics.

Bull Confirmed If

An EPS of $3.71 or higher would confirm strong demand for AbbVie's products.

Bear Confirmed If

An EPS below $3.54 would raise concerns about the company's growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±5.85%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±5.8% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

23.2%

Calls (444K)P/C Ratio: 0.73Puts (307K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests the stock could rise by an average of 1.78% on the following day, confirming strong demand.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may remain volatile as investors reassess growth prospects.

Miss

A miss could lead to a decline of around 0.15%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key products in the immunology segment.
2Any new developments in AbbVie's pipeline that could impact future growth.
3Management's insights on competitive pressures in the biotechnology space.
4Guidance on revenue expectations for the next quarter.
5Comments on market conditions and their impact on sales.